Purdue Pharma L.P.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$67.0M
Doctors Paid
18,457
Transactions
76,141
2024 Total
$2.5M
Payment Breakdown by Category
Research$38.3M (57.2%)
Consulting$24.6M (36.8%)
Food & Beverage$1.1M (1.6%)
Travel$136,774 (0.2%)
Royalty/License$1,200 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.3M | 1,615 | 57.2% |
| Consulting Fee | $24.6M | 607 | 36.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 1,281 | 3.4% |
| Food and Beverage | $1.1M | 71,952 | 1.6% |
| Grant | $497,334 | 21 | 0.7% |
| Travel and Lodging | $136,774 | 634 | 0.2% |
| Honoraria | $21,970 | 2 | 0.0% |
| Charitable Contribution | $14,541 | 6 | 0.0% |
| Education | $11,551 | 7 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $6,890 | 11 | 0.0% |
| Royalty or License | $1,200 | 5 | 0.0% |
Payments by Type
Research
$38.3M
1,615 transactions
General
$28.6M
74,526 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| HVB1001 | $5.9M | 0 | 34 |
| VAN2001 | $3.7M | 0 | 302 |
| NAL1002 | $3.5M | 0 | 20 |
| NAL9001 | $2.8M | 1 | 23 |
| OAG1006 | $2.8M | 0 | 5 |
| OAG1010 | $2.6M | 0 | 7 |
| BOX1001 | $2.5M | 0 | 11 |
| An open-label, multicenter, multiple-dose, safety and tolerability study of Adhansia XR extended-release capsules in children 4 to 12 years of age | $1.6M | 3 | 170 |
| Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | $1.5M | 15 | 388 |
| 063-015 | $1.5M | 0 | 43 |
| OAG1008 | $943,948 | 0 | 10 |
| A Two-Part Study to Characterize the Pharmacokinetics of Nalmefene Hydrochloride and to Assess the Time Course of Reversal and Breakthrough of Opioid Agonist Effects Following Naloxone and Nalmefene Administration | $919,395 | 0 | 6 |
| PMR 2923-2 study of OxyContin utilization among pediatric patients | $904,535 | 0 | 58 |
| PMR 2923-2 A Nationally Representative Drug Utilization Study of OxyContin in Children Aged 17 Years and Younger | $864,710 | 0 | 11 |
| TKA1005 | $858,990 | 0 | 6 |
| NAL1003 | $748,748 | 0 | 5 |
| 063-020 | $612,232 | 0 | 23 |
| OEB9001 | $576,045 | 0 | 4 |
| Clinical Outcomes from Injectable Nalmefene in the Emergency Department | $478,080 | 0 | 6 |
| Cost and Prevalence of Opioid Abuse | $415,000 | 0 | 3 |
| The Effect of Primary Care Opioid Taper Plans on Sustained Opioid Taper | $361,363 | 0 | 5 |
| OxyContin Utilization in Pediatric Patients: Prescribing Trends from 2011-2018; PMR2923-2 | $342,234 | 0 | 7 |
| ER/LA Opioid PMR -bservational Studies 1A/1B/3A | $301,865 | 0 | 9 |
| TKA2001 | $224,458 | 0 | 136 |
| Neuroimaging Effects of Cognitive Behavioral Therapy in Fibromyalgia | $158,100 | 0 | 4 |
| Alpha as a Predictive Biomarker (APB) | $152,046 | 0 | 2 |
| PMR 3033-11: Study 11 | $131,365 | 10 | 57 |
| Changes in Rates of Opioid Overdose and Poisoning Events in the Kaiser Permanente Health System with the Introduction of Reformulated OxyContin | $110,704 | 0 | 2 |
| 063-017 | $109,216 | 0 | 11 |
| A Pragmatic, Single Arm Trial of Prehospital Nalmefene for Treatment of Opioid Toxicity in a Population with High Fentanyl Use | $105,475 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Abraham Cherrick, Md, MD | Physical Medicine & Rehabilitation | Alexandria, VA | $21,928 | $0 |
| Khyber Zaffarkhan, D.o, D.O | Physical Medicine & Rehabilitation | Newport Beach, CA | $21,806 | $0 |
| Charles Montano, Md, MD | Internal Medicine | Cromwell, CT | $21,595 | $0 |
| Dr. Daniel Halpert, Do, DO | Physical Medicine & Rehabilitation | Culpeper, VA | $21,135 | $0 |
| Margie Sander, M.d, M.D | Family Medicine | Durham, NC | $18,172 | $0 |
| Dr. Thomas Robey, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | New Haven, CT | $17,693 | $0 |
| Dr. Gerald Sacks, M.d, M.D | Pain Medicine | Santa Monica, CA | $16,452 | $0 |
| Jorge Lujan-Zilbermann, M.d, M.D | Pediatrics | Tampa, FL | $16,207 | $0 |
| Dr. David Krakow, Md, MD | Psychosomatic Medicine | New York, NY | $16,003 | $0 |
| Sheldon Goldberg, Md, MD | Physical Medicine & Rehabilitation | Lakewood, CO | $15,959 | $0 |
| Julio Flamini, M.d, M.D | Neurology | Atlanta, GA | $15,513 | $0 |
| David Lichten, Md, MD | Physical Medicine & Rehabilitation | Pottstown, PA | $15,027 | $0 |
| Dr. Craig Surman, Md, MD | Psychiatry | Cambridge, MA | $15,013 | $0 |
| Unknown Provider | — | — | $14,135 | $0 |
| Andrew Blauvelt, Md, MD | Dermatology | Portland, OR | $13,705 | $0 |
| Dr. Joel Young, Md, MD | Psychiatry | Rochester Hills, MI | $13,478 | $0 |
| Dr. Paul Choi, M.d, M.D | Pain Medicine | Irvine, CA | $13,252 | $0 |
| Leonard Kamen, D.o, D.O | Physical Medicine & Rehabilitation | Elkins Park, PA | $12,850 | $0 |
| Dr. Howard Maibach, M.d, M.D | Dermatology | San Francisco, CA | $12,838 | $0 |
| Dr. Richard Jackson, M.d, M.D | Psychiatry | Bloomfield Hills, MI | $12,758 | $0 |
| Dr. William Doss, M.d, M.D | Pain Medicine | Bryan, TX | $11,617 | $0 |
| Howard Hochster, M.d, M.D | Hematology | New Haven, CT | $11,541 | $0 |
| Dr. Dean Mariano, Do, DO | Pain Medicine | Carmel, IN | $10,680 | $0 |
| Abhijeet Rastogi, Md, MD | Pain Medicine | Hainesport, NJ | $10,348 | $0 |
| Dr. Sunil Panchal, Md, MD | Pain Medicine | Lutz, FL | $9,447 | $0 |
Ad
Top Products
- OXYCONTIN $7.8M
- ADHANSIA XR $3.3M
Associated Products (6)
- OXYCONTIN $7.8M
- NALMEFENE HYDROCHLORIDE $1.7M
- HYSINGLA ER $1.2M
- SYMPROIC $1.0M
- Oxycontin $415,000
- BUTRANS $151,810
Payment Categories
- Food & Beverage $1.1M
- Consulting $24.6M
- Travel & Lodging $136,774
- Research $38.3M
- Royalties $1,200
About Purdue Pharma L.P.
Purdue Pharma L.P. has made $67.0M in payments to 18,457 healthcare providers, recorded across 76,141 transactions in the CMS Open Payments database. In 2024, the company paid $2.5M. The top product by payment volume is OXYCONTIN ($7.8M).
Payments were distributed across 167 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 3,460 doctors).
Payment categories include: Food & Beverage ($1.1M), Consulting ($24.6M), Research ($38.3M), Travel & Lodging ($136,774), Royalties ($1,200).
Purdue Pharma L.P. is associated with 6 products in the CMS Open Payments database, including OXYCONTIN, NALMEFENE HYDROCHLORIDE, and HYSINGLA ER.